# Elise Wang

> Elise Wang is a Series A investor at Deerfield backing Biotechnology. See 5 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: Angel Investor
- Fund: [Deerfield](https://shizune.co/investors/profile/deerfield)
- Location: New York, United States
- Total investments: 5
- Last investment: Jun 2024
- Lead investor: 40%
- Last updated: Sep 2026
- LinkedIn: https://www.linkedin.com/in/elise-wang-08bb451

Elise Wang is a Series A investor at Deerfield in New York focused on Biotechnology and Medical. As an Analyst on the Private Transactions team, Elise provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Prior to joining Deerfield in 2010, Elise began her career in healthcare in 1987 as a venture capitalist and banker at PaineWebber Inc. and was an officer ofPaineWebber Development Corporation, which managed nearly $1.0 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. From 1996 to 2007, Elise was a Senior Research Analyst and Managing Director in healthcare primarily covering the biotechnology industry at PaineWebber Inc. (1996-2001) and Citigroup (2001-2007). She holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School.

## Contacts

5 contacts available for Elise Wang: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/elise-wang?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 80% |
| Medical | 1 | 20% |
| Genetics | 1 | 20% |
| Biopharma | 1 | 20% |
| Health Care | 1 | 20% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 20% |
| Series B | 1 | 20% |
| Series C | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 60% |
| United Kingdom | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Advanced Medicine Partners | Advanced Medicine Partners is a biotechnology company that specializes in viral vector manufacturing for genes and cells. | $32M | Series A | Jun 05, 2024 |  |
| HilleVax | HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts. | $135M | Venture - Series Unknown | Sep 08, 2021 |  |
| Werewolf Therapeutics | Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. | $72M | Series B | Jan 07, 2021 |  |
| Werewolf Therapeutics | Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. | $72M | Series B | Jan 07, 2021 |  |
| Orchard Therapeutics | Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. Theseprograms include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston. | $150M | Series C | Aug 13, 2018 |  |

5 of 5 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 4 deals together
- [Sphera Global Healthcare Fund](https://shizune.co/investors/profile/sphera-global-health-care-fund) — VC Fund, 3 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 2 deals together
- [Arkin Bio Ventures](https://shizune.co/investors/profile/arkin-bio-ventures) — VC Fund, 2 deals together
- [CaaS Capital Management](https://shizune.co/investors/profile/caas-capital-management) — VC Fund, 2 deals together
- [DC Investment Partners](https://shizune.co/investors/profile/dc-investment-partners) — VC Fund, 2 deals together

## About Deerfield

VC Fund · New York, United States

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

5 contacts available at Deerfield.

| Name | Title | Profile |
| --- | --- | --- |
| Alexander Karnal | Partner and Managing Director | https://shizune.co/investors/profile/alex-karnal |
| Andrew ElBardissi | Partner | https://shizune.co/investors/profile/andrew-elbardissi |
| Bryan Sendrowski | Partner | https://shizune.co/investors/profile/bryan-sendrowski |
| Cameron Wheeler | Principal | https://shizune.co/investors/profile/cameron-wheeler |
| Elise Wang | Partner, Head of Private Equity Capital Markets | https://shizune.co/investors/profile/elise-wang |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Elise Wang invest in?

Elise Wang invests primarily in Biotechnology, Medical and Genetics startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Elise Wang?

Public channels for Elise Wang include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Elise Wang last invest?

The most recent investment recorded for Elise Wang closed in Jun 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co